ArticleArthritis and rheumatism2007
British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus.
Article in Arthritis and rheumatism, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Does baricitinib reduce disease activity in patients with systemic lupus erythematosus? A systematic review and meta-analysis of randomized controlled trials.Clinical rheumatology · 2024Pooled it
- Trial
- Causal cascade of direct and indirect effects of anifrolumab on patient-reported outcomes: structural equation modelling of two Phase 3 trials.Rheumatology (Oxford, England) · 2022Trial
- Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.Annals of the rheumatic diseases · 2014Trial
- A Review and Future Perspective on Renal Outcome Definitions in Lupus Nephritis.ACR open rheumatology · 2026Review
- [What is proven in the treatment of systemic lupus erythematosus?]Innere Medizin (Heidelberg, Germany) · 2023Review
- Lupus clinical trials and the promise of future therapies.Rheumatology and immunology research · 2023Article
- Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE.Lupus science & medicine · 2023Article
- The BILAG-2004 index is associated with development of new damage in SLE.Rheumatology (Oxford, England) · 2023Article
- How can we accurately measure disease activity during pregnancy in systemic lupus erythematosus? New insights from the BILAG-2004 Pregnancy Index.Rheumatology advances in practice · 2023Article
- Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally.Arthritis care & research · 2022Article
- Serum amyloid A-to-albumin ratio as a potential biomarker to predict the activity, severity, and poor prognosis of systemic lupus erythematosus.Journal of clinical laboratory analysis · 2022Article
- The BILAG2004-Pregnancy Index is a valid disease activity outcome measure for pregnant SLE patients.Rheumatology advances in practice · 2022Article
- Vitronectin, a Novel Urinary Proteomic Biomarker, Promotes Cell Pyroptosis in Juvenile Systemic Lupus Erythematosus.Mediators of inflammation · 2022Article
- Clinical disease activity and flare in SLE: Current concepts and novel biomarkers.Journal of autoimmunity · 2021Review
- Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures.Lupus science & medicine · 2019Article
- Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations.Arthritis research & therapy · 2018Article
- IL-16/miR-125a axis controls neutrophil recruitment in pristane-induced lung inflammation.JCI insight · 2018Article
- Influence of autoimmunity and inflammation on endothelial function and thrombosis in systemic lupus erythematosus patients.Clinical rheumatology · 2018Article
- Does erythrocyte sedimentation rate reflect and discriminate flare from infection in systemic lupus erythematosus? Correlation with clinical and laboratory parameters of disease activity.Clinical rheumatology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectiveTo determine the construct and criterion validity of the British Isles Lupus Assessment Group 2004 (BILAG-2004) index for assessing disease activity in systemic lupus erythematosus (SLE).
methodsPatients with SLE were recruited into a multicenter cross-sectional study. Data on SLE disease activity (scores on the BILAG-2004 index, Classic BILAG index, and Systemic Lupus Erythematosus Disease Activity Index 2000 [SLEDAI-2K]), investigations, and therapy were collected. Overall BILAG-2004 and overall Classic BILAG scores were determined by the highest score achieved in any of the individual systems in the respective index. Erythrocyte sedimentation rates (ESRs), C3 levels, C4 levels, anti-double-stranded DNA (anti-dsDNA) levels, and SLEDAI-2K scores were used in the analysis of construct validity, and increase in therapy was used as the criterion for active disease in the analysis of criterion validity. Statistical analyses were performed using ordinal logistic regression for construct validity and logistic regression for criterion validity. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated.
resultsOf the 369 patients with SLE, 92.7% were women, 59.9% were white, 18.4% were Afro-Caribbean and 18.4% were South Asian. Their mean +/- SD age was 41.6 +/- 13.2 years and mean disease duration was 8.8 +/- 7.7 years. More than 1 assessment was obtained on 88.6% of the patients, and a total of 1,510 assessments were obtained. Increasing overall scores on the BILAG-2004 index were associated with increasing ESRs, decreasing C3 levels, decreasing C4 levels, elevated anti-dsDNA levels, and increasing SLEDAI-2K scores (all P < 0.01). Increase in therapy was observed more frequently in patients with overall BILAG-2004 scores reflecting higher disease activity. Scores indicating active disease (overall BILAG-2004 scores of A and B) were significantly associated with increase in therapy (odds ratio [OR] 19.3, P < 0.01). The BILAG-2004 and Classic BILAG indices had comparable sensitivity, specificity, PPV, and NPV.
conclusionThese findings show that the BILAG-2004 index has construct and criterion validity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.